The firm reported preliminary financial results in line with previous guidance and the average Wall Street estimate.
The firm signed a memorandum of understanding with the agency and is expected to detail the terms of the cooperation in a subsequent collaborative agreement.
The agreement extends Cepheid's reach beyond the hospital lab environment into the moderately complex lab space.
The test is the first of several planned CLIA-waived assays from Cepheid, and the first point-of-care test on the market to differentiate flu from RSV.
The partners are broadening their collaboration to bring point-of-care TB diagnostics to all levels of the health system in low- and middle-income countries.
Wells Fargo downgraded Cepheid from Outperform to Market Perform, citing the firm's "credibility and visibility" following a revised 2017 outlook.
At the AMP meeting this week, JHU's Sara Sukumar discussed efforts to adapt a cell-free methylated DNA assay for breast cancer to a Cepheid Xpert cartridge.
The GenomeWeb Index was up around 2 percent, but its performance was well behind the broader stock market.
The firm claimed delays in a planned sales force expansion were partly to blame for lower-than-expected revenues; it also announced the FDA clearance of an assay for Trichomonas vaginalis.
The investment bank issued its downgrade citing concerns about changes to Cepheid's sales force and a flattening of its MRSA assay sales.
Mainichi reports that 43 percent of Japanese individuals said they did not want to eat agricultural products that had been modified using gene-editing tools.
Two US Department of Agriculture research departments are moving to the Kansas City area, according to the Washington Post.
Slate's Jane Hu compares some at-home genetic tests to astrology.
In PLOS this week: analysis of polygenic risk scores for skin cancer, chronic pain GWAS, and more.